The partnership with Therapure builds upon BioVectra’s expertise in the production of modified biologic molecules using a proprietary MPEG technology.
Therapure, from its 130,000 square feet facilities in Mississauga, Ontario, is said to add proprietary purification techniques and formulation, fill, and finish expertise in biologics handling.
Thomas Wellner, president and CEO of Therapure Biopharma, said: “We are very excited about working with BioVectra. They bring significant expertise in active pharmaceutical ingredient development and a high degree of competence and commitment to our partnership.”